Introducing Laurie DeLeve, M.D., Ph.D., Our 2022 AASLD President
Neil Kaplowitz – 5 December 2021
Suppressed farnesoid X receptor by iron overload in mice and humans potentiates iron‐induced hepatotoxicity
Hui Xiong, Chunze Zhang, Lifeng Han, Tong Xu, Khawar Saeed, Jing Han, Jing Liu, Curtis D. Klaassen, Frank J. Gonzalez, Yuanfu Lu, Youcai Zhang – 5 December 2021
Frailty, mortality, and health care utilization after liver transplantation: From the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study
Jennifer C. Lai, Amy M. Shui, Andres Duarte‐Rojo, Daniel R. Ganger, Robert S. Rahimi, Chiung‐Yu Huang, Frederick Yao, Matthew Kappus, Brian Boyarsky, Mara McAdams‐Demarco, Michael L. Volk, Michael A. Dunn, Daniela P. Ladner, Dorry L. Segev, Elizabeth C. Verna, Sandy Feng, from the Multi‐Center Functional Assessment in Liver Transplantation (FrAILT) Study – 3 December 2021
Letter to the editor: Exacerbation of autoimmune hepatitis after COVID‐19 vaccination
Zhujun Cao, Honglian Gui, Zike Sheng, Haiguang Xin, Qing Xie – 3 December 2021
Big Data for Small People: How Novel Data Collection Can Improve Pediatric Transplantation Outcomes
M. Andrew Millis, Shannon L. Cramm, Michael Englesbe – 2 December 2021
Reply
Andrew I. Aronsohn, Debika Bhattacharya, Timothy R. Morgan, David L. Wyles, Raymond T. Chung, Daniel P. McQuillen, AASLD‐IDSA HCV Guidance – 2 December 2021
Secondary Prophylaxis of Gastric Variceal Bleeding: A Systematic Review and Network Meta‐Analysis
Karim T. Osman, Tarek Nayfeh, Ahmed M. Abdelfattah, Khaled Alabdallah, Bashar Hasan, Mohammed Firwana, Homam Alabaji, Lina Elkhabiry, Jehan Mousa, Larry J. Prokop, M. Hassan Murad, Fredric Gordon – 2 December 2021 – There is no clear consensus regarding the optimal approach for secondary prophylaxis of gastric variceal bleeding (GVB) in patients with cirrhosis. We conducted a systematic review and network meta‐analysis (NMA) to compare the efficacy of available treatments.
The use of nondirected donor organs in living donor liver transplantation: Perspectives and guidance
Alyson N. Fox, AnnMarie Liapakis, Ramesh Batra, Therese Bittermann, Juliet Emamaullee, Sukru Emre, Yuri Genyk, Hyosun Han, Whitney Jackson, Elizabeth Pomfret, Muhammad Raza, Manuel Rodriguez‐Davalos, Susan Rubman Gold, Benjamin Samstein, Akhil Shenoy, Timucin Taner, John P.
A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis
Cihan Yurdaydin, Onur Keskin, Esra Yurdcu, Aysun Çalişkan, Soner Önem, Fatih Karakaya, Çağdaş Kalkan, Ersin Karatayli, Senem Karatayli, Ingrid Choong, David Apelian, Christopher Koh, Theo Heller, Ramazan Idilman, A. Mithat Bozdayi, Jeffrey S. Glenn – 2 December 2021
Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?
Gonzalo Sapisochin, Tommy Ivanics, Julie Heimbach – 2 December 2021 – Cholangiocarcinoma (CCA) represents the second‐most common primary liver malignancy after HCC and has risen in incidence globally in the past decades. Intrahepatic cholangiocarcinoma (iCCA) comprises 20% of all CCAs, with the rest being extrahepatic (including perihilar [pCCA] and distal CCA). Though long representing an absolute contraindication for liver transplantation (LT), recent analyses of outcomes of LT for iCCA have suggested that iCCA may be a potentially feasible option for highly selected patients.